HK1132268A1 - Novel anxiolytic compounds - Google Patents
Novel anxiolytic compoundsInfo
- Publication number
- HK1132268A1 HK1132268A1 HK09111778.6A HK09111778A HK1132268A1 HK 1132268 A1 HK1132268 A1 HK 1132268A1 HK 09111778 A HK09111778 A HK 09111778A HK 1132268 A1 HK1132268 A1 HK 1132268A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- anxiolytic compounds
- novel anxiolytic
- novel
- compounds
- anxiolytic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85198306P | 2006-10-16 | 2006-10-16 | |
PCT/AU2007/001566 WO2008046135A1 (fr) | 2006-10-16 | 2007-10-16 | Nouveaux composés anxiolytiques |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1132268A1 true HK1132268A1 (en) | 2010-02-19 |
Family
ID=39313499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09111778.6A HK1132268A1 (en) | 2006-10-16 | 2009-12-15 | Novel anxiolytic compounds |
Country Status (13)
Country | Link |
---|---|
US (7) | US8293737B2 (fr) |
EP (2) | EP2074123B1 (fr) |
JP (4) | JP5373613B2 (fr) |
AU (1) | AU2007312936B2 (fr) |
CA (2) | CA2666219C (fr) |
DK (1) | DK2074123T3 (fr) |
ES (1) | ES2399071T3 (fr) |
HK (1) | HK1132268A1 (fr) |
NZ (1) | NZ576036A (fr) |
PL (1) | PL2074123T3 (fr) |
PT (1) | PT2074123E (fr) |
SI (1) | SI2074123T1 (fr) |
WO (1) | WO2008046135A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2074123T3 (pl) | 2006-10-16 | 2013-04-30 | Bionomics Ltd | Nowe związki o działaniu przeciwlękowym |
US10954231B2 (en) * | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
WO2011031745A1 (fr) | 2009-09-09 | 2011-03-17 | Achaogen, Inc. | Analogues de fluoroquinolone antibactériens |
AU2012222874B2 (en) * | 2011-03-02 | 2015-04-16 | Bionomics Limited | Novel small-molecules as therapeutics |
US20140051701A1 (en) * | 2011-03-02 | 2014-02-20 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
CN103649086A (zh) * | 2011-05-12 | 2014-03-19 | 生态学有限公司 | 制备萘啶的方法 |
WO2014036595A1 (fr) * | 2012-09-04 | 2014-03-13 | Bionomics Limited | Composés et procédés de traitement de maladies ou d'états associés au système nerveux central et/ou à l'excroissance des neurites |
US9745296B2 (en) * | 2013-03-15 | 2017-08-29 | Bionomics Limited | Salts, co-crystals, and polymorphs of an anxiolytic compound |
AU2013204159B2 (en) | 2013-03-15 | 2015-05-07 | Bionomics Limited | A Crystalline Form of an Anxiolytic Compound |
WO2019109150A1 (fr) * | 2017-12-07 | 2019-06-13 | Bionomics Limited | Procédés de traitement de l'agitation |
EP3867252B1 (fr) | 2018-10-18 | 2023-12-06 | Bionomics Limited | Dérivés de 6-indan-2-yloxy-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one et composés similaires en tant que modulateurs du récepteur nicotinique alpha 7 de l'acétylcholine pour le traitement de l'anxiété |
CN114585362B (zh) * | 2019-09-23 | 2024-05-07 | 生态有限公司 | 治疗制剂及其用途 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1022214A (en) * | 1963-01-31 | 1966-03-09 | Sterling Drug Inc | Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation |
US3429887A (en) * | 1965-01-26 | 1969-02-25 | Sterling Drug Inc | 1,7-naphthyridine-3-carboxylic acid derivatives and their preparation |
US3506668A (en) * | 1965-01-26 | 1970-04-14 | Sterling Drug Inc | Method of preparing 8-hydroxy-quinolines |
JPS5023037B1 (fr) | 1970-12-29 | 1975-08-05 | ||
JPS5023036B1 (fr) | 1970-12-29 | 1975-08-05 | ||
JPS5023037A (fr) * | 1973-07-03 | 1975-03-12 | ||
JPS5023036A (fr) | 1973-07-06 | 1975-03-12 | ||
JPS5132594A (en) | 1974-09-11 | 1976-03-19 | Kanebo Ltd | 1 88 nafuchirijinjudotai no seiho |
JPS5331690A (en) * | 1976-09-01 | 1978-03-25 | Shionogi & Co Ltd | Oxadithiacephalosporins |
JPS54163596A (en) * | 1978-06-09 | 1979-12-26 | Daiichi Seiyaku Co | Flonaphlizine derivative |
JPS55111486A (en) * | 1979-02-19 | 1980-08-28 | Dai Ichi Seiyaku Co Ltd | Preparation of pro 3,2,-b -1,8-naphthyridine derivative |
JPS55151584A (en) | 1979-05-11 | 1980-11-26 | Dai Ichi Seiyaku Co Ltd | Preparation of 1,8-naphthyridine derivative |
JPS56115787A (en) | 1980-02-19 | 1981-09-11 | Dai Ichi Seiyaku Co Ltd | Preparation of furo (3,2-b)(1,8)naphthyridine derivative |
JPS56118083A (en) | 1980-02-22 | 1981-09-16 | Dai Ichi Seiyaku Co Ltd | Furo(3,2-b)(1,8)naphthyridine derivative |
JPS56118081A (en) | 1980-02-22 | 1981-09-16 | Dai Ichi Seiyaku Co Ltd | Preparation of 6-methoxy-1,8-naphthyridine |
JPS5726688A (en) | 1980-07-24 | 1982-02-12 | Dai Ichi Seiyaku Co Ltd | Furo 3,2-b 1,8-naphthyridine-7-carboxylic acid derivative |
JPS57109790A (en) | 1980-12-26 | 1982-07-08 | Dai Ichi Seiyaku Co Ltd | Furo(3,2-b)1,8-naphthyridine-7-carboxylic acid derivative |
US4404201A (en) * | 1981-11-13 | 1983-09-13 | Warner-Lambert Company | Cephalosporins |
JPS5993080A (ja) | 1982-11-18 | 1984-05-29 | Sumitomo Chem Co Ltd | 1,5−ナフチリジンカルボン酸誘導体 |
DE68919273T2 (de) | 1988-05-10 | 1995-03-23 | Ici Pharma | Cephalosporine, Verfahren zu ihrer Herstellung und pharmazeutische Präparate. |
US5095015A (en) * | 1990-07-24 | 1992-03-10 | Neurogen Corporation | Certain azacycloalkyl imidazopyrimidines; a new class of gaba brain receptor ligands |
US5182290A (en) * | 1991-08-27 | 1993-01-26 | Neurogen Corporation | Certain oxazoloquinolinones; a new class of GABA brain receptor ligands |
US5182386A (en) * | 1991-08-27 | 1993-01-26 | Neurogen Corporation | Certain imidazoquinoxalinones; a new class of gaba brain receptor ligands |
IT1251202B (it) * | 1991-09-13 | 1995-05-04 | Mediolanum Farmaceutici Spa | 6-amminochinoloni, sintesi ed impiego come antibatterici |
US5212310A (en) * | 1991-12-19 | 1993-05-18 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
US5306819A (en) * | 1992-08-27 | 1994-04-26 | Neurogen Corporation | Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands |
US5750702A (en) * | 1993-10-27 | 1998-05-12 | Neurogen Corporation | Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands |
US5484944A (en) * | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
US6211365B1 (en) * | 1996-01-19 | 2001-04-03 | Neurogen Corporation | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands |
US5804686A (en) * | 1996-01-19 | 1998-09-08 | Neurogen Corporation | fused pyrrolecarboxamides; a new class of GABA brain receptor ligands |
US6013650A (en) * | 1996-03-14 | 2000-01-11 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
AU2218997A (en) * | 1996-03-22 | 1997-10-10 | Neurogen Corporation | Certain fused pyrrolecarboxamides as gaba brain receptor ligands |
US5723462A (en) * | 1996-04-26 | 1998-03-03 | Neurogen Corporation | Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands |
HUP0003258A3 (en) * | 1997-08-25 | 2001-05-28 | Neurogen Corp Branford | Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands |
US6143760A (en) * | 1997-08-25 | 2000-11-07 | Neurogen Corporation | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands |
AU2793199A (en) * | 1998-02-26 | 1999-09-15 | Neurogen Corporation | 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives,their preparation and their use as (ant-)agonists for gaba (a) brain receptors |
DE19826050A1 (de) | 1998-06-12 | 1999-12-16 | Bayer Ag | Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester |
US6177569B1 (en) * | 1998-08-25 | 2001-01-23 | Neurogen Corporation | Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands |
AU2217200A (en) * | 1998-12-23 | 2000-07-12 | Neurogen Corporation | 2-amino-9-alkylpurines: gaba brain receptor ligands |
EP1177177B1 (fr) * | 1999-05-06 | 2005-02-23 | Neurogen Corporation | 4-oxo-quinoline-3-carboxamides substitues: ligands des recepteurs cerebraux gaba |
US6297256B1 (en) * | 1999-06-15 | 2001-10-02 | Neurogen Corporation | Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands |
WO2001034603A2 (fr) * | 1999-11-12 | 2001-05-17 | Neurogen Corporation | Composes heteroaromatiques bicycliques et tricycliques |
US6723332B2 (en) * | 2000-05-26 | 2004-04-20 | Neurogen Corporation | Oxomidazopyridine-carboxamides |
WO2002000623A2 (fr) * | 2000-06-26 | 2002-01-03 | Neurogen Corporation | 4-oxy-pyridines substituees a fusion aryle |
US6423956B1 (en) * | 2000-07-28 | 2002-07-23 | Optical Biopsy Technologies | Fiber-coupled, high-speed, integrated, angled-dual-axis confocal scanning microscopes employing vertical cross-section scanning |
ATE307127T1 (de) * | 2000-08-16 | 2005-11-15 | Neurogen Corp | 2,4-substituierte pyridinderivate |
CA2419966A1 (fr) * | 2000-09-06 | 2002-03-14 | Neurogen Corporation | Tetrahydroindazoles substitues par aryle et leur utilisation comme ligands pour le recepteur de gaba-a |
US20020151591A1 (en) * | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
AUPR283801A0 (en) | 2001-02-01 | 2001-03-01 | Australian National University, The | Chemical compounds and methods |
OA12554A (en) * | 2001-03-01 | 2006-06-07 | Pfizer Prod Inc | Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders. |
EP1392692B1 (fr) * | 2001-03-27 | 2006-11-15 | Neurogen Corporation | (oxo-pyrazolo¬1,5a|pyrimidin-2-yl)alkyl-carboxamides |
CA2468015A1 (fr) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | Composes de 2-aminoquinoline |
AU2002352868A1 (en) | 2001-11-27 | 2003-06-10 | Merck & Co., Inc. | 4-aminoquinoline compounds |
WO2003097564A2 (fr) | 2002-05-14 | 2003-11-27 | The Regents Of The University Of California | Acides quinolone carboxyliques substitues, derives de ces derniers, site d'action et utilisations de ces derniers |
IS7839A (is) | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
AR042486A1 (es) * | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . |
JP2005162726A (ja) * | 2003-01-24 | 2005-06-23 | Tanabe Seiyaku Co Ltd | ピラゾロピリミジン化合物およびその製法 |
TW200418835A (en) | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
US20050031652A1 (en) | 2003-02-25 | 2005-02-10 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
WO2004083207A1 (fr) * | 2003-03-12 | 2004-09-30 | Abbott Laboratories | Derives de naphthyridine comme agents antibacteriens |
US7402674B2 (en) * | 2004-01-31 | 2008-07-22 | Sanofi-Aventis Deutschland Gmbh, | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
DE102004004971B3 (de) | 2004-01-31 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel |
RU2006131306A (ru) | 2004-01-31 | 2008-03-10 | Санофи-Авентис Дойчланд Гмбх (De) | Производные 7-фениламино-4-хинолон-3-карбоновой кислоты, способ их получения и их применение в качестве лекарственных средств |
US7470706B2 (en) * | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
DE102004004972B3 (de) * | 2004-01-31 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Heterocyclisch substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7498341B2 (en) * | 2004-01-31 | 2009-03-03 | Sanofi Aventis Deutschland Gmbh | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
JP2008517963A (ja) | 2004-11-01 | 2008-05-29 | エフ.ホフマン−ラ ロシュ アーゲー | Gaba−b受容体のアロステリックエンハンサーとしてのキノリン |
WO2006060390A1 (fr) | 2004-12-03 | 2006-06-08 | Merck & Co., Inc. | Antagonistes de récepteurs de tachykinine de type quinoline |
EP1893560A2 (fr) | 2005-06-02 | 2008-03-05 | F. Hoffmann-Roche AG | 3-methanesulfonylquinolines renforçant le gaba-b |
JP5183479B2 (ja) | 2005-09-29 | 2013-04-17 | サノフイ | フェニル基を有するフェニル−[1,2,4]−オキサジアゾール−5−オン誘導体、その製造方法、及び医薬品としてのその使用 |
TW200824678A (en) | 2006-08-11 | 2008-06-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
PL2074123T3 (pl) | 2006-10-16 | 2013-04-30 | Bionomics Ltd | Nowe związki o działaniu przeciwlękowym |
AR076687A1 (es) | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen |
CN106278999B (zh) | 2011-02-07 | 2019-10-25 | 比奥根Ma公司 | S1p调节剂 |
US20140051701A1 (en) | 2011-03-02 | 2014-02-20 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
AU2012222874B2 (en) | 2011-03-02 | 2015-04-16 | Bionomics Limited | Novel small-molecules as therapeutics |
CN103649086A (zh) | 2011-05-12 | 2014-03-19 | 生态学有限公司 | 制备萘啶的方法 |
-
2007
- 2007-10-16 PL PL07815371T patent/PL2074123T3/pl unknown
- 2007-10-16 EP EP07815371A patent/EP2074123B1/fr active Active
- 2007-10-16 NZ NZ576036A patent/NZ576036A/en not_active IP Right Cessation
- 2007-10-16 SI SI200731109T patent/SI2074123T1/sl unknown
- 2007-10-16 US US12/311,872 patent/US8293737B2/en active Active
- 2007-10-16 CA CA2666219A patent/CA2666219C/fr active Active
- 2007-10-16 JP JP2009531697A patent/JP5373613B2/ja active Active
- 2007-10-16 CA CA2954376A patent/CA2954376C/fr active Active
- 2007-10-16 ES ES07815371T patent/ES2399071T3/es active Active
- 2007-10-16 AU AU2007312936A patent/AU2007312936B2/en active Active
- 2007-10-16 WO PCT/AU2007/001566 patent/WO2008046135A1/fr active Application Filing
- 2007-10-16 DK DK07815371.5T patent/DK2074123T3/da active
- 2007-10-16 PT PT78153715T patent/PT2074123E/pt unknown
- 2007-10-16 EP EP12186384.9A patent/EP2540722B1/fr active Active
-
2009
- 2009-12-15 HK HK09111778.6A patent/HK1132268A1/xx unknown
-
2012
- 2012-09-14 US US13/617,317 patent/US8614212B2/en active Active
- 2012-09-14 US US13/617,153 patent/US8551990B2/en active Active
-
2013
- 2013-05-20 JP JP2013106650A patent/JP5739476B2/ja active Active
- 2013-09-18 US US14/030,808 patent/US8906912B2/en active Active
-
2014
- 2014-11-05 US US14/533,808 patent/US9573945B2/en active Active
-
2015
- 2015-04-23 JP JP2015088672A patent/JP6138191B2/ja active Active
-
2017
- 2017-01-04 US US15/398,472 patent/US9975892B2/en active Active
- 2017-02-08 JP JP2017021529A patent/JP6506322B2/ja active Active
- 2017-12-15 US US15/844,295 patent/US10233181B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1132268A1 (en) | Novel anxiolytic compounds | |
EP2034838A4 (fr) | Nouveaux composés | |
EP2032142A4 (fr) | Nouveaux composés | |
EP1981596A4 (fr) | Nouveaux composés | |
GB0603550D0 (en) | Novel compounds | |
EP1981900A4 (fr) | Nouveaux composés | |
GB0605462D0 (en) | Novel compounds | |
GB0602900D0 (en) | Novel Compounds | |
EP2031965A4 (fr) | Nouveaux composés | |
GB0607840D0 (en) | Novel compounds | |
GB0600483D0 (en) | Novel compounds | |
GB0608452D0 (en) | Novel compounds | |
GB0607892D0 (en) | Novel compounds | |
GB0624901D0 (en) | Novel compounds E | |
GB0608567D0 (en) | Novel compounds | |
GB0601288D0 (en) | Novel compounds | |
GB0602800D0 (en) | Novel Compounds | |
GB0610924D0 (en) | Novel compounds | |
GB0608978D0 (en) | Novel compounds | |
GB0608976D0 (en) | Novel compounds | |
GB0602237D0 (en) | Novel compounds | |
GB0608566D0 (en) | Novel compounds | |
GB0608457D0 (en) | Novel compounds | |
GB0608455D0 (en) | Novel compounds | |
GB0602133D0 (en) | Novel compounds |